In this captivating episode, we dive deep into the groundbreaking intersection of artificial intelligence and enzyme engineering with David Schönauer, founder and CEO of Aminoverse.
From university lab benches to pioneering AI-driven enzyme discovery, David shares how his startup is transforming the biotech landscape by making enzyme development faster, more predictable, and increasingly efficient.
Highlights:
David's journey from academic researcher to biotech entrepreneur offers invaluable lessons for scientists considering the entrepreneurial path. His practical approach to combining cutting-edge AI with traditional wet lab techniques demonstrates how modern biotechnology can solve real-world problems while maintaining scientific rigor.
Ready to explore the future of biotech? Listen now to learn how AI is transforming enzyme engineering and what it means for the future of sustainable technology, pharmaceuticals, and more.
Connect with David Schönauer:
LinkedIn: https://www.linkedin.com/in/david-schönauer
Aminoverse: https://www.aminoverse.com
Next Steps:
Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment
Ready to revolutionize your biologics development? Our Fractional CTO services help you develop better, faster, and more cost-effectively. Leverage your full potential today — book a free consultation at https://bruehlmann-consulting.com and let's accelerate your success!